Sargramostim (rhu GM-CSF) and Immune Checkpoint Inhibitors : Combinatorial Therapeutic Studies in Metastatic Melanoma(Post)
Metastatic melanoma presents significant treatment challenges, but advancements in immunotherapy, particularly the combination of Sargramostim (rhu GM-CSF) and immune checkpoint inhibitors, offer pr ...
Product results
Product results
- Product
- Qty in Cart
- Quantity
- Price
- Subtotal
-
SHIKARI Q-NIVO (Nivolumab) ELISA | 30121608
€2,026.70SHIKARI Q-NIVO (Nivolumab) ELISA | 30121608 | IBL International Application: ELISA Category Type: Immunology181-30121608€2,026.70 -
SHIKARI S-ATN (Anti-Nivolumab-Ab) ELISA | 30124464
€2,026.70SHIKARI S-ATN (Anti-Nivolumab-Ab) ELISA | 30124464 | IBL International Application: ELISA Category Type: Immunology181-30124464€2,026.70